Podocyte cultures and uses thereof
US-2015376575-A1 · Dec 31, 2015 · US
US9316633B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9316633-B2 |
| Application number | US-51499207-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 16, 2007 |
| Priority date | Nov 16, 2006 |
| Publication date | Apr 19, 2016 |
| Grant date | Apr 19, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are methods for identifying and characterizing agents that alter the volume of a cell. Methods are provided for rapid screening and identification of an agent that alters the capability of a small, neutrally charged solute transporter to transport the solute across a cell membrane. The methods described herein may be used to identify and characterize inhibitors of urea transporters, to identify and characterize inhibitors of aquaporins, and to identify and characterize inhibitors of other small, neutrally charged solutes such as glucose.
Opening claim text (preview).
We claim the following: 1. A method for treating a disease or disorder associated with a urea clearance insufficiency in a subject, said method comprising administering to the subject a composition comprising a pharmaceutically suitable excipient and a compound that inhibits transport of urea by the urea transporter across a cell membrane, wherein the compound is selected from N-benzyl-4-(4-chlorophenylsulfonyl)-2-(2-fluorophenyl)oxazol-5-amine; 5-(methylthio)-4-(phenylsulfonyl)-2-p-tolyl-1H-imidazole; 2-phenyl-4-tosyl-1H-imidazole-5-thiol; and S-2-phenyl-4-(phenylsulfonyl)-1H-imidazol-5-yl benzothioate. 2. The method of claim 1 , wherein the disease or disorder is selected from a cardiovascular disease, syndrome of inappropriate antidiuretic hormone secretion (SIADH), cirrhosis, azotemia, acute renal failure, chronic renal insufficiency, fluid retention, diabetes, and abnormal uresis. 3. The method of claim 1 wherein the urea transporter is Urea Transporter-B (UT-B).
on cell morphology · CPC title
involving cells · CPC title
involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)} · CPC title
Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title
involving urea · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.